Shares of Innate Pharma (Euronext Paris: IPH) were almost 14% higher at 2.34 euros by late morning on the news that it has expanded its collaboration with fellow France-based pharma major Sanofi (Euronext: SAN), licensing a natural killer (NK) cell engager program targeting B7H3 from Innate’s ANKET (Antibody-based NK Cell Engager Therapeutics) platform.
Sanofi will also have the option to add up to two additional ANKET targets and, following target selection, Sanofi will be responsible for all development, manufacturing and commercialization.
The companies signed their first NK cell engagers deal in 2016 for the generation and evaluation of up to two bispecific NK cell engagers, which are currently being evaluated by Sanofi’s R&D team, with one of these molecules already in clinical studies. In July this year, Sanofi made the decision to progress IPH6401/SAR’514 into investigational new drug (IND)-enabling studies, triggering an around $3 million milestone payment.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze